RxDoctor Payments Data

Harjeet Singh, MD

Internal Medicine · Bakersfield, CANPI 1003956863

Payments from drug & device makers

$815in general payments, 2019–2025

Across 27 payments — averaging $30.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$151
  • Actelion Pharmaceuticals US, Inc.$144
  • Angiodynamics, Inc.$115
  • E.r. Squibb & Sons, L.L.C.$109
  • GSK$108
  • Lilly USA, LLC$54
  • plus $134 from 6 others

What the payments were for

  • Food & beverage$815100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$815 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$40,007
Medicare patients
60
Services billed
717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$42,768
FarxigaDapagliflozin Propanediol13$11,643
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$6,779
Atorvastatin Calcium210$1,489
Tamsulosin Hcl95$1,208
Metformin Hcl164$860
Albuterol Sulfate HfaAlbuterol Sulfate27$768
Gabapentin100$745
Losartan Potassium83$661
Levothyroxine Sodium39$620
Memantine Hcl29$563
Omeprazole76$543
Rosuvastatin Calcium38$497
Lisinopril80$443
FenofibrateFenofibrate Nanocrystallized24$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$16$42,76853 claims
AstraZenecaFarxiga$151$11,64313 claims
GSKTrelegy Ellipta$108$6,77912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →